Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2115-9. doi: 10.1007/s00259-007-0589-9. Epub 2007 Sep 21.

Abstract

Purpose: The aim of this study was to determine whether the follow-up of pain processing recovery in hyperalgesic fibromyalgia (FM) could be objectively evaluated with brain perfusion ethyl cysteinate dimer single photon computerized tomography (ECD-SPECT) after administration of ketamine.

Materials and methods: We enrolled 17 hyperalgesic FM women patients (48.5 +/- 11 years, range 25-63). After treatment with subcutaneous ketamine, 11 patients were considered as "good responders", with a decrease in pain intensity, evaluated by visual analog scale (VAS), greater than 50%. On the other hand, six patients were considered as "poor responders". A voxel-based analysis of regional cerebral blood flow (rCBF) was conducted (p (voxel) < 0.001uc), in the two subgroups of patients, before and after treatment, in comparison to a group of ten healthy subjects, matched for age and gender.

Results: In comparison to baseline brain SPECT, midbrain rCBF showed a greater increase after ketamine in the responder group than in the nonresponder group (p (cluster) = 0.016c). In agreement with the clinical response, the change in midbrain rCBF after ketamine was highly correlated with the reduction of VAS pain score (r = 0.7182; p = 0.0041).

Conclusion: This prospective study suggests that blockade of facilitatory descending modulation of pain with ketamine can be evaluated in the periaqueductal grey with brain perfusion SPECT.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Anesthetics, Dissociative / therapeutic use
  • Brain / diagnostic imaging*
  • Cysteine / analogs & derivatives*
  • Female
  • Fibromyalgia / diagnostic imaging*
  • Fibromyalgia / drug therapy*
  • Follow-Up Studies
  • Humans
  • Hyperalgesia / diagnostic imaging*
  • Hyperalgesia / prevention & control*
  • Ketamine / therapeutic use*
  • Male
  • Middle Aged
  • Organotechnetium Compounds*
  • Pain / diagnostic imaging
  • Pain / prevention & control
  • Pain Measurement / drug effects
  • Pain Measurement / methods*
  • Radiopharmaceuticals
  • Tomography, Emission-Computed, Single-Photon / methods
  • Treatment Outcome

Substances

  • Anesthetics, Dissociative
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • Ketamine
  • technetium Tc 99m bicisate
  • Cysteine